JP2016538840A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538840A5 JP2016538840A5 JP2016526026A JP2016526026A JP2016538840A5 JP 2016538840 A5 JP2016538840 A5 JP 2016538840A5 JP 2016526026 A JP2016526026 A JP 2016526026A JP 2016526026 A JP2016526026 A JP 2016526026A JP 2016538840 A5 JP2016538840 A5 JP 2016538840A5
- Authority
- JP
- Japan
- Prior art keywords
- rhaga
- protein
- column
- pccs2
- mccs1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020005541A JP7296327B2 (ja) | 2013-10-23 | 2020-01-17 | 組み換え糖タンパク質及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894879P | 2013-10-23 | 2013-10-23 | |
| US61/894,879 | 2013-10-23 | ||
| US201361901942P | 2013-11-08 | 2013-11-08 | |
| US61/901,942 | 2013-11-08 | ||
| PCT/US2014/061789 WO2015061464A2 (en) | 2013-10-23 | 2014-10-22 | Recombinant glycoproteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020005541A Division JP7296327B2 (ja) | 2013-10-23 | 2020-01-17 | 組み換え糖タンパク質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016538840A JP2016538840A (ja) | 2016-12-15 |
| JP2016538840A5 true JP2016538840A5 (https=) | 2017-11-30 |
| JP6837334B2 JP6837334B2 (ja) | 2021-03-03 |
Family
ID=51871299
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526026A Active JP6837334B2 (ja) | 2013-10-23 | 2014-10-22 | 組み換え糖タンパク質及びその使用 |
| JP2020005541A Active JP7296327B2 (ja) | 2013-10-23 | 2020-01-17 | 組み換え糖タンパク質及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020005541A Active JP7296327B2 (ja) | 2013-10-23 | 2020-01-17 | 組み換え糖タンパク質及びその使用 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US11208644B2 (https=) |
| EP (2) | EP3060660B1 (https=) |
| JP (2) | JP6837334B2 (https=) |
| KR (2) | KR102479886B1 (https=) |
| CN (3) | CN105916984A (https=) |
| AU (2) | AU2014340152A1 (https=) |
| BR (1) | BR112016008086A2 (https=) |
| CA (1) | CA2927852A1 (https=) |
| CL (1) | CL2016000961A1 (https=) |
| CR (1) | CR20160225A (https=) |
| DK (1) | DK3060660T3 (https=) |
| DO (1) | DOP2016000079A (https=) |
| EA (1) | EA034515B1 (https=) |
| ES (1) | ES2882562T3 (https=) |
| HR (1) | HRP20211197T1 (https=) |
| HU (1) | HUE055236T2 (https=) |
| IL (2) | IL245255B (https=) |
| LT (1) | LT3060660T (https=) |
| MX (1) | MX392532B (https=) |
| MY (2) | MY197247A (https=) |
| NZ (1) | NZ720384A (https=) |
| PE (1) | PE20160723A1 (https=) |
| PH (1) | PH12016500708B1 (https=) |
| PL (1) | PL3060660T3 (https=) |
| PT (1) | PT3060660T (https=) |
| RS (1) | RS62171B1 (https=) |
| SG (2) | SG11201602932WA (https=) |
| SI (1) | SI3060660T1 (https=) |
| TN (1) | TN2016000140A1 (https=) |
| TW (3) | TW202332774A (https=) |
| UA (1) | UA119857C2 (https=) |
| UY (1) | UY35794A (https=) |
| WO (1) | WO2015061464A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| AU2017266932B2 (en) * | 2016-05-18 | 2023-04-20 | Modernatx, Inc. | Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease |
| CA3039673A1 (en) | 2016-10-20 | 2018-04-26 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of fabry disease |
| TW201829770A (zh) * | 2017-01-10 | 2018-08-16 | 美商阿米庫斯醫療股份有限公司 | 用於治療fabry氏病之重組α-半乳糖苷酶A |
| WO2025092951A1 (en) * | 2023-11-03 | 2025-05-08 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant adeno-associated viral vectors for treating fabry disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5356804A (en) * | 1990-10-24 | 1994-10-18 | Mount Sinai School Of Medicine Of The City Of New York | Cloning and expression of biologically active human α-galactosidase A |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) * | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| JP4001925B2 (ja) * | 1996-09-13 | 2007-10-31 | トランスカーヨティック セラピーズ インク． | α―ガラクトシダーゼＡ欠損症の治療 |
| IL135578A0 (en) | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
| US20020081654A1 (en) * | 2000-04-07 | 2002-06-27 | Sandrin Mauro Sergio | Targeting hydrolase enzymes |
| US7138262B1 (en) * | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| US7133354B2 (en) | 2002-08-26 | 2006-11-07 | Qualcomm Incorporated | Synchronization techniques for a wireless system |
| DE60335024D1 (de) * | 2002-12-23 | 2010-12-30 | Bristol Myers Squibb Co | Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion |
| CN100522988C (zh) * | 2003-04-09 | 2009-08-05 | 诺和诺德公司 | 糖peg化方法及由该方法生产的蛋白质/肽 |
| WO2008120107A2 (en) * | 2007-04-03 | 2008-10-09 | Oxyrane (Uk) Limited | Glycosylation of molecules |
| AU2008291358A1 (en) | 2007-08-31 | 2009-03-05 | F. Hoffmann-La Roche Ag | Glycosylation profile analysis |
| US9034341B2 (en) * | 2009-04-20 | 2015-05-19 | Transtech Pharma, Llc | Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions |
| WO2011107990A1 (en) * | 2010-03-02 | 2011-09-09 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| US20120178105A1 (en) | 2011-01-10 | 2012-07-12 | Genzyme Corporation | Detection of globotriaosylceramide (glc) in human urine samples using an antibody sandwich |
| CN103443270B (zh) * | 2011-01-20 | 2017-06-06 | 普罗塔里克斯有限公司 | 用于在植物和植物细胞中表达α‑半乳糖苷酶的核酸构建体 |
| JP6329483B2 (ja) * | 2011-10-12 | 2018-05-23 | シナジェバ・バイオファーマ・コーポレイションＳｙｎａｇｅｖａ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐ． | 組換えヒトｎａｇｌｕタンパク質およびその利用 |
| EP2620506A1 (en) | 2012-01-25 | 2013-07-31 | Arla Foods Amba | Method of producing a galacto-oligosaccharide-containing composition |
| TWI528785B (zh) | 2013-02-08 | 2016-04-01 | 瑞昱半導體股份有限公司 | 立體影像的調整裝置及其方法 |
| SG10201709131UA (en) | 2013-03-08 | 2017-12-28 | Genzyme Corp | Continuous purification of therapeutic proteins |
-
2014
- 2014-10-21 TW TW111139854A patent/TW202332774A/zh unknown
- 2014-10-21 TW TW103136272A patent/TWI642782B/zh active
- 2014-10-21 TW TW107130267A patent/TWI793159B/zh active
- 2014-10-22 CN CN201480070424.3A patent/CN105916984A/zh active Pending
- 2014-10-22 KR KR1020217027690A patent/KR102479886B1/ko active Active
- 2014-10-22 US US15/030,555 patent/US11208644B2/en active Active
- 2014-10-22 DK DK14796346.6T patent/DK3060660T3/da active
- 2014-10-22 WO PCT/US2014/061789 patent/WO2015061464A2/en not_active Ceased
- 2014-10-22 EA EA201690826A patent/EA034515B1/ru not_active IP Right Cessation
- 2014-10-22 MY MYPI2019005029A patent/MY197247A/en unknown
- 2014-10-22 ES ES14796346T patent/ES2882562T3/es active Active
- 2014-10-22 PE PE2016000543A patent/PE20160723A1/es unknown
- 2014-10-22 SG SG11201602932WA patent/SG11201602932WA/en unknown
- 2014-10-22 RS RS20210960A patent/RS62171B1/sr unknown
- 2014-10-22 MX MX2016005321A patent/MX392532B/es unknown
- 2014-10-22 PL PL14796346T patent/PL3060660T3/pl unknown
- 2014-10-22 BR BR112016008086A patent/BR112016008086A2/pt not_active Application Discontinuation
- 2014-10-22 CN CN202110161563.9A patent/CN112852784A/zh active Pending
- 2014-10-22 JP JP2016526026A patent/JP6837334B2/ja active Active
- 2014-10-22 CA CA2927852A patent/CA2927852A1/en active Pending
- 2014-10-22 PT PT147963466T patent/PT3060660T/pt unknown
- 2014-10-22 CN CN202210146800.9A patent/CN114606217A/zh active Pending
- 2014-10-22 LT LTEPPCT/US2014/061789T patent/LT3060660T/lt unknown
- 2014-10-22 NZ NZ720384A patent/NZ720384A/en unknown
- 2014-10-22 EP EP14796346.6A patent/EP3060660B1/en active Active
- 2014-10-22 SI SI201431857T patent/SI3060660T1/sl unknown
- 2014-10-22 KR KR1020167013333A patent/KR102298080B1/ko active Active
- 2014-10-22 PH PH1/2016/500708A patent/PH12016500708B1/en unknown
- 2014-10-22 HU HUE14796346A patent/HUE055236T2/hu unknown
- 2014-10-22 AU AU2014340152A patent/AU2014340152A1/en not_active Abandoned
- 2014-10-22 TN TN2016000140A patent/TN2016000140A1/en unknown
- 2014-10-22 MY MYPI2016700943A patent/MY178632A/en unknown
- 2014-10-22 EP EP20183936.2A patent/EP3778884A1/en active Pending
- 2014-10-22 SG SG10201803366PA patent/SG10201803366PA/en unknown
- 2014-10-22 HR HRP20211197TT patent/HRP20211197T1/hr unknown
- 2014-10-22 UA UAA201605455A patent/UA119857C2/uk unknown
- 2014-10-23 UY UY0001035794A patent/UY35794A/es not_active Application Discontinuation
-
2016
- 2016-04-11 DO DO2016000079A patent/DOP2016000079A/es unknown
- 2016-04-21 CL CL2016000961A patent/CL2016000961A1/es unknown
- 2016-04-21 IL IL245255A patent/IL245255B/en active IP Right Grant
- 2016-05-17 CR CR20160225A patent/CR20160225A/es unknown
-
2020
- 2020-01-17 JP JP2020005541A patent/JP7296327B2/ja active Active
- 2020-02-11 IL IL272609A patent/IL272609B/en unknown
- 2020-12-21 AU AU2020294173A patent/AU2020294173A1/en not_active Abandoned
-
2021
- 2021-09-22 US US17/482,193 patent/US20220064617A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016538840A5 (https=) | ||
| Wallach et al. | Advances in the treatment of neuromyelitis optica spectrum disorder | |
| JP2013231081A5 (https=) | ||
| GB0102687D0 (en) | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them | |
| JP2012041356A5 (https=) | ||
| MXPA02012164A (es) | Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden. | |
| IL159843A0 (en) | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| MXPA05009719A (es) | Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden. | |
| Gane et al. | Phase 1a safety and pharmacokinetics of NVR 3-778, a potential first-in-class HBV core inhibitor: LB-19 | |
| IL160744A0 (en) | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| WO2006102596A3 (en) | Dosage regimen for the treatment of a traumatic brain injury with progesterone | |
| EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
| JP2011528895A5 (https=) | ||
| MY204380A (en) | Nonracemic mixtures and uses thereof | |
| FI3581199T3 (fi) | Menetelmiä turvottavan fibroskleroottisen pannikulopatian hoitamiseksi tai vähentämiseksi | |
| Nishikawa et al. | Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease | |
| RU2022104034A (ru) | Фармацевтические композиции | |
| JP2017537927A5 (https=) | ||
| WO2016109823A8 (en) | Treatment of pediatric growth hormone deficiency with human growth hormone analogues | |
| WO2007078895A3 (en) | Modified release formulations of tramadol and uses thereof | |
| Scheerens et al. | Treatment with MEMP1972A, an anti-M1 prime monoclonal antibody, reduced serum IgE in healthy volunteers and patients with allergic rhinitis | |
| KR20240132521A (ko) | 항-tnf-알파 폴리펩티드 조성물 및 그 용도 | |
| Sousa et al. | Hands-on laboratory class for biopharmaceutical pDNA quality control | |
| ES2184561A1 (es) | Forma farmaceutica solida de administracion oral dispersable en agua para el tratamiento de la tuberculosis conteniendo refampicina, isoniazida, pirazinamida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. | |
| RU2011127055A (ru) | Лекарственное средство для лечения неврологическо-поведенческих расстройств развития и способ лечения неврологическо-поведенческих расстройств развития |